한국인 산모에서 다운증후군 산전선별검사로서의 통합선별검사의 유용성 평가

키워드

참고문헌 (34)

1. Cuckle HS, "Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome", Lancet, 1, pp.926~929 (1984)
2. Wald NJ, "Maternal serum screening for Down’s syndrome in early pregnancy", BMJ, 297, pp.883~887 (1988)
3. Van Lith JM, "Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down’s syndrome", Prenat Diagn, 12, pp.801~806 (1992)
4. Wald NJ, "Prenatal screening for Down’s syndrome using inhibin-A as a serum marker", Prenat Diagn, 16, pp.143~153 (1996)
5. Malone FD, "First-trimester or second-trimester screening, or both, for Down’s syndrome", N Engl J Med, 353, pp.2001~2011 (2005)
6. Wald NJ, "First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS)", J Med Screen, 10, pp.56~104 (2003)
7. Malone FD, "First-trimester sonographic screening for Down syndrome", Obstet Gynecol, 102, pp.1066~1079 (2003)
8. Nicolaides KH, "Ultrasonographically detectable markers of fetal chromosomal abnormalities", Lancet, 340, pp.704~707 (1992)
9. Brizot ML, "Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy", Obstet Gynecol, 84, pp.918~922 (1994)
10. Spencer K, "Free beta-hCG as first-trimester marker for fetal trisomy", Lancet, 339, pp.1480~ (1992)
11. Wald NJ, "Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies", Prenat Diagn, 23, pp.588~592 (2003)
12. Wapner RJ, "First trimester screening: the BUN study", Semin Perinatol, 29, pp.236~239 (2005)
13. Bindra R, "One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies", Ultrasound Obstet Gynecol, 20, pp.219~225 (2002)
14. 김솔잎, "국내 생화학적 표지자 산전선별검사 기초조사 보고", Annals of Laboratory Medicine, 27(1), pp.28~33 (2007), 대한진단검사의학회
15. Hwang D, "Prenatal screening using maternal serum AFP, uE3 and hCG in Korean pregnant women: about the correction of MoM value according to maternal weight", Korean J Obstet Gynecol, 38, pp.378~388 (1995)
16. Dallaire L, "Integration of prenatal diagnosis of genetic diseases into medical practice", Can Med Assoc J, 115, pp.713~714 (1976)
17. Caron L, "Frequencies of chromosomal abnormalities at amniocentesis: over 20 years of cytogenetic analyses in one laboratory", Am J Med Genet, 82, pp.149~154 (1999)
18. ACOG educational bulletin, "Maternal serum screening. Number 228, September 1996 (replaces no. 154, April 1991)", Int J Gynaecol Obstet, 55, pp.299~308 (1996), College of Obstetricians and Gynecologists
19. ACOG Committee on Practice Bulletins, "ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities", Obstet Gynecol, 109, pp.217~227 (2007)
20. Wald NJ, "Antenatal screening for Down’s syndrome", J Med Screen, 4, pp.181~246 (1997)
21. Pandya PP, "De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation", Br J Obstet Gynaecol, 102, pp.957~962 (1995)
22. Snijders RJ, "First-trimester ultrasound screening for chromosomal defects", Ultrasound Obstet Gynecol, 7, pp.216~226 (1996)
23. Snijders RJ, "UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation", Lancet, 352, pp.343~346 (1998), Fetal Medicine Foundation First Trimester Screening Group
24. Taipale P, "Increased nuchal translucency as a marker for fetal chromosomal defects", N Engl J Med, 337, pp.1654~1658 (1997)
25. Cuckle HS, "Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level", Br J Obstet Gynaecol, 94, pp.387~402 (1987)
26. Wald NJ, "Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down’s syndrome", J Med Screen, 7, pp.74~77 (2000)
27. Cho HJ, "Determination of Reference Level for Triple Marker in Korean Population", J Lab Med Qual Assur, 26, pp.185~192 (2004)
28. Spencer K, "The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy", Prenat Diagn, 25, pp.927~929 (2005)
29. Webster RA, "Henry’s clinical diagnosis and management by laboratory methods", pp.373~ (2007), Saunders Elsevier
30. O’Brien JE, "Raceethnicity-specific variation in multiple-marker biochemical screening: alpha-fetoprotein, hCG, and estriol", Obstet Gynecol, 89, pp.355~358 (1997)
31. Crossley JA, "Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotropin, and effect on detection of Down syndrome pregnancies in second-trimester screening", Prenat Diagn, 22, pp.247~255 (2002)
32. Dashe JS, "Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound", Am J Obstet Gynecol, 195, pp.1623~1628 (2006)
33. Kagan KO, "Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A", Ultrasound Obstet Gynecol, 32, pp.488~492 (2008)
34. Breathnach FM, "First- and second-trimester screening: detection of aneuploidies other than Down syndrome", Obstet Gynecol, 110, pp.651~657 (2007)

관련 논문AI추천